An observational study in Chronic Obstructive Pulmonary Disease Exacerbation, sponsored by Wim Janssens. Recruiting at 22 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.
Sponsored by Wim Janssens · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 539 studies in Pulmonary Disease, Chronic Obstructive with a site in Germany — 33 open to participants now, 46 under way, 10 of them phase 3. Pulmonary Disease, Chronic Obstructive · Germany.
Among the 539 studies in Pulmonary Disease, Chronic Obstructive with a site in Germany, this one is the 20th largest by planned enrollment of the 96 observational ones that give a count, is one of 17 that started in 2022, is one of 97 observational ones, reaches primary completion later than 20 of the 45 other live ones, and was the 463rd registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →33 of the 539 studies in Pulmonary Disease, Chronic Obstructive with a site in Germany are open now. Recruiting first, the newest first:
Fraunhofer-Institute of Toxicology and Experimental Medicine · Sites in Germany
Ages 40+
Eli Lilly and Company · Sites in Germany, United States, Argentina and 15 more countries
Ages 40–75
Grifols Therapeutics LLC · Sites in Germany, United States, Denmark and 6 more countries
Ages 18–80
Pfizer · Sites in Germany, United States, Argentina and 15 more countries
Ages 35–80
AstraZeneca · Sites in Germany, United Kingdom
Ages 40–80
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
539 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 44 · Phase 2 103 · Phase 3 146 · Phase 4 51
First in 2000; this study’s year is marked. 17 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 159 across 1,498 observational studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 156 across the 441 interventional studies, 178 across the 96 observational. Of the 456 that completed or were terminated, 232 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
400 of 539 have an industry lead sponsor. The 10 most frequent:
Wim Janssens is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Wim Janssens has 5 studies filed under Pulmonary Disease, Chronic Obstructive — fewer than ten, so there is no comparison to draw.
15 of the studies in Pulmonary Disease, Chronic Obstructive with a site in Germany that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05878769Phase 3Hoffmann-La RocheA Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | 2027-06-30 |
| NCT07555483Phase 3Grifols Therapeutics LLCA Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD) | 2027-09-30 |
| NCT07751705Fraunhofer-Institute of Toxicology and Experimental MedicineInduced Sputum Collection in COPD Patients With and Without a Vibroacoustic Device | 2026-12 |
| NCT06712563AstraZenecaPooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting | 2026-12-14 |
| NCT06154837GlaxoSmithKlineA Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease | 2026-12-16 |
Add all 15 to your calendar (.ics) → With an account.
Among the 539 studies in Pulmonary Disease, Chronic Obstructive with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The CATALINA study is a prospective cohort study embedded within CICERO (Collaboration In COPD ExaceRbatiOns, a European Respiratory Society supported Clinical Research Collaboration), designed to collect standardised, longitudinal clinical data and biological samples in 20 centres across Europe and beyond.
The initial objective is to recruit 1000 patients hospitalised for an acute COPD exacerbation by the end of CICERO's first lifecycle (3 years), from whom 1 year follow-up data and biological samples will be collected. By doing so, CICERO aims to develop a comprehensive European COPD patient data- and biobank phenotyped in relation to the exacerbation, to support the development of future EU-wide clinical intervention trials in COPD for specific patient subgroups, as well as new prognostication tools for COPD exacerbations.
The clinical data and biological samples will be obtained during 6 scheduled study visits, during the hospitalization period of the index acute exacerbation as well as the outpatient setting after hospital discharge; and 3 additional unscheduled study visits should the patient be readmitted for respiratory reasons during study participation (i.e. first readmission only).
3 study visits will be scheduled during the hospitalization period of the index acute exacerbation:
3 study visits will be scheduled during the outpatient setting:
The first hospital readmission for respiratory reasons during the patient's study participation will undergo the same testing schedule as mandated during the hospitalization period of the index event:
Resulting from CICERO's future lifecycles will be the continued expansion of the data- and bio-bank, both in cohort size and duration of follow-up.
Patients with COPD, hospitalized for an acute exacerbation
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All-cause mortality
Death from any cause
Time frame: Will be assessed during 1 year, on visits 2-6
Step-up in hospital care for respiratory reasons
A composite outcome measure defined as: 1. New hospitalization for respiratory reasons 2. Hospital care intensification from baseline (ie. within 24h from hospital admission) for respiratory reasons, including: * 2.1 Non-invasive respiratory therapy (oxygen by mask or nasal flow) * 2.2 Non-invasive respiratory therapy (oxygen by NIV or high flow) * 2.3 Invasive respiratory therapy (intubation and mechanical ventilation) * 2.4 Physiological support with inotropes
Time frame: Will be assessed during 1 year, on visits 2-6
Treatment intensification for respiratory reasons
A composite outcome measure defined as: 1. Prolongation of systemic corticosteroids \>5 days administered for the index acute exacerbation or first readmission for respiratory reasons 2. Upgrade of antibiotics administered for the index exacerbation or first readmission for respiratory reasons 3. New course of systemic corticosteroids for respiratory reasons 4. New course of antibiotics for respiratory reasons
Time frame: Will be assessed during 1 year, on visits 2-6
Treatment failure
A composite outcome measure defined as: 1. All-cause mortality 2. Step-up in hospital care for respiratory reasons 3. Treatment intensification for respiratory reasons
Time frame: Will be assessed during 1 year, on visits 2-6
Severe treatment failure
As intensification of drug treatment regimens and treatment intensifications are country/region-specific and not always related to failure of disease control, severe treatment failure (STF) will be defined as the composite of: 1. All-cause mortality 2. Step-up in hospital care for respiratory reasons
Time frame: Will be assessed during 1 year, on visits 2-6
Readmission for a severe COPD exacerbation
Readmission of the patient to the hospital for a severe COPD exacerbation
Time frame: Will be assessed during 1 year, on visits 2-6
New hospitalization for respiratory reasons
New admission of the patient to the hospital for respiratory reasons
Time frame: Will be assessed during 1 year, on visits 2-6
Hospital care intensification for respiratory reasons
A composite outcome measure defined as: 1. Non-invasive respiratory therapy (oxygen by mask or nasal flow) 2. Non-invasive respiratory therapy (oxygen by NIV or high flow) 3. Invasive respiratory therapy (intubation and mechanical ventilation) 4. Physiological support with inotropes
Time frame: Will be assessed during 1 year, on visits 2-6
Time to
The time to the following outcomes will be measured: 1. All-cause mortality 2. First hospital readmission for respiratory reasons 3. Hospital care intensification for respiratory reasons 4. Treatment intensification for respiratory reasons 5. Treatment failure 6. Severe treatment failure
Time frame: Will be assessed during 1 year, on visits 2-6
Number of participants with a new or changed Do Not Resuscitate (DNR) code
The implementation of a new or changed DNR code during study participation will be measured. * DNR 0: do not restrict therapy (i.e. explicit statement not to withhold any life-sustaining interventions) * DNR 1: do not resuscitate, further specified as: DNR 1a: No CPR DNR 1b: No CPR + no intubation + NIV to be considered * DNR 2: do not extend therapy (i.e. no CPR + no intubation + no NIV) * DNR 3: discontinue therapy (i.e. no CPR + no intubation + no NIV + withdrawal of current treatment°) Abbreviations: CPR, cardiopulmonary resuscitation; NIV, non-invasive ventilation; °, treatment of disabling symptoms to be prioritised, however, no life-prolonging interventions are to be continued
Time frame: Will be assessed during 1 year, on visits 2-6
Cumulative dose of systemic corticosteroids
The total dose of systemic corticosteroids administered during study participation will be measured.
Time frame: Will be assessed during 1 year, on visits 2-6
Total days in hospital
Total number of days spent in a hospital during study participation will be measured.
Time frame: Will be assessed during 1 year, on visits 2-6
Change in modified Medical Research Council (mMRC): a dyspnea scale
The change in the following patient reported outcome measures (PROM) will be measured: modified Medical Research Council (mMRC): a dyspnea scale * scale: 0 to 4 * interpretation: higher scores indicate worse outcome
Time frame: Will be assessed during 1 year, on visits 2-6
Change in COPD Assessment Test (CAT): a COPD impact scale
The change in the following patient reported outcome measures (PROM) will be measured: COPD Assessment Test (CAT): a COPD impact scale * scale: 0 to 40 * interpretation: higher scores indicate worse outcome
Time frame: Will be assessed during 1 year, on visits 2-6
Change in Patient Health Questionnaire-9 (PHQ-9): a depression scale
The change in the following patient reported outcome measures (PROM) will be measured: Patient Health Questionnaire-9 (PHQ-9): a depression scale * scale: 0 to 29 * interpretation: higher scores indicate worse outcome
Time frame: Will be assessed during 1 year, on visits 2-6
Change in Generalized Anxiety Disorder-7 (GAD-7): an anxiety scale
The change in the following patient reported outcome measures (PROM) will be measured: Generalized Anxiety Disorder-7 (GAD-7): a anxiety scale * scale: 0 to 21 * interpretation: higher scores indicate worse outcome
Time frame: Will be assessed during 1 year, on visits 2-6
Change in patient reported experience measure (PREM)
The change in the following PREM will be measured: 1\. Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS): measuring patients' perceptions of their hospital experience -interpretation: higher scores indicate better outcome
Time frame: Will be assessed during 1 year, on visits 2-6
Change in comorbidities
Changes in baseline comorbidies (ie. the appearance of new or worsening of existing) will be measured
Time frame: Will be assessed during 1 year, on visits 2-6
Change in biomarker Eotaxin-3 (CCL26)
Eotaxin-3 is a small cytokine belonging to the CC chemokine family (called CCL26, Chemokine (C-C motif) ligand 26). Eotaxin-3 is chemotactic for eosinophils and basophils and elicits its effects by binding to the cell surface chemokine receptor CCR3.
Time frame: Will be assessed during 1 year, on visits 2-6
Change in biomarker IL-5
Interleukin-5 (IL-5) acts on mature eosinophils, leading to proliferation, activation, differentiation, and survival; playing a critical role in the host immune response to infections.
Time frame: Will be assessed during 1 year, on visits 2-6
Change in biomarker IL-33
Interleukin-33 (IL-33) is described as an inducer of type 2 immune responses, activating T helper 2 cells and mast cells.
Time frame: Will be assessed during 1 year, on visits 2-6
Change in biomarker MCP-4 (CCL13)
Monocyte chemotactic protein 4 (MCP-4), also called CCL13, is a major chemo-attractant for eosinophils, basophils, monocytes and T lymphocytes
Time frame: Will be assessed during 1 year, on visits 2-6
Change in biomarker TARC4 (CCL17)
Thymus and activation regulated chemokine (TARC), also known as CCL17, is a chemokine that induces chemotaxis of Type 2 T helper (Th2) cells.
Time frame: Will be assessed during 1 year, on visits 2-6
Change in biomarker IP-10 (CXCL10)
Interferon gamma-induced protein 10 (IP-10 (CXCL10)) chemoattracts Th1 lymphocytes and monocytes, and inhibits cytokine-stimulated hematopoietic progenitor cell proliferation.
Time frame: Will be assessed during 1 year, on visits 2-6
Change in biomarker IL1A
Interleukin 1 alpha (IL1A) stimulates the activity of genes involved in inflammation and immunity
Time frame: Will be assessed during 1 year, on visits 2-6
Change in biomarker IL-8
Interleukin 8 (IL-8) is a chemokine produced by macrophages and other cell types such as epithelial cells, airway smooth muscle cells and endothelial cells; which attracts and activates neutrophils in inflammatory regions
Time frame: Will be assessed during 1 year, on visits 2-6
Change in biomarker GM-CSF
Granulocyte-macrophage colony-stimulating factor (GM-CSF) regulates proliferation and/or activation of monocytes, macrophages, neutrophils and eosinophils
Time frame: Will be assessed during 1 year, on visits 2-6
Not enrolling at this site — choose another above.
Started Oct 2022 (actual). Primary completion is estimated for Mar 2027, 53 months after the start.
Of 469 non-industry observational studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 62. This study's planned 53 months is above that.
Counting every sponsor, half of 589 studies reached it within 26 months; a quarter within 14 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →
Wim Janssens